Skip to main content

Boehringer Ingelheim Expands Oncology Portfolio With $991 Million AimedBio Antibody-Drug Conjugate Deal

Submitted by J. Mikhail on
Image
Boehringer Ingelheim Expands Oncology Portfolio With $991 Million AimedBio Antibody-Drug Conjugate Deal

SHERIDAN, WYOMING – October 15, 2025 – Boehringer Ingelheim is continuing its high-stakes investment strategy in next-generation oncology treatments, signing a deal worth up to $991 million with South Korea’s AimedBio to license an antibody-drug conjugate (ADC) for cancer. The move underscores Boehringer’s accelerating focus on precision oncology and reinforces its growing footprint in the ADC space—one of the most competitive frontiers in cancer therapeutics.

Bristol Myers Squibb Extends $2B+ AI Drug Discovery Pact with Insitro to Advance ALS Research

Submitted by J. Mikhail on
Image
Bristol Myers Squibb Extends $2B+ AI Drug Discovery Pact with Insitro to Advance ALS Research

SHERIDAN, WYOMING – October 15, 2025 – Bristol Myers Squibb (BMS) has expanded its artificial intelligence-driven collaboration with insitro, reinforcing its long-term strategy to accelerate therapeutic development in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The renewed deal underscores a shared commitment to leveraging AI and advanced chemistry platforms to unlock new pathways in ALS drug discovery.

AI-Powered Extension Strengthens a Five-Year Alliance

BioCryst Expands Hereditary Angioedema Portfolio with $700M Astria Therapeutics Acquisition

Submitted by J. Mikhail on
Image
BioCryst Expands Hereditary Angioedema Portfolio with $700M Astria Therapeutics Acquisition

SHERIDAN, WYOMING – October 15, 2025 – BioCryst Pharmaceuticals is strengthening its hereditary angioedema (HAE) pipeline through the acquisition of Massachusetts-based Astria Therapeutics in a $700 million cash-and-stock deal. The move positions BioCryst to compete more aggressively in the rare disease market by combining its oral HAE treatment, Orladeyo, with Astria’s long-acting injectable candidate, navenibart.

FDA Grants Krystal Biotech Platform Technology Designation, Marking Strategic Shift in Gene Therapy Oversight

Submitted by J. Mikhail on
Image
FDA Grants Krystal Biotech Platform Technology Designation, Marking Strategic Shift in Gene Therapy Oversight

SHERIDAN, WYOMING – October 15, 2025 – In a pivotal development for the U.S. biotech sector, Krystal Biotech has received the U.S. Food and Drug Administration’s (FDA) second-ever platform technology designation for its non-replicating HSV-1 viral vector—positioning the company as a key early beneficiary of the agency’s emerging regulatory framework for gene therapy platforms.

Validation of a Versatile Gene Delivery Platform

Heidelberg and MK Masterwork Extend Strategic Partnership to Drive Automation in Global Packaging Production

Submitted by J. Mikhail on
Image
Heidelberg and MK Masterwork Extend Strategic Partnership to Drive Automation in Global Packaging Production

SHERIDAN, WYOMING – October 15, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) and China’s MK Masterwork are deepening their decade-long collaboration to advance automation and robotics in packaging production. The renewed strategic partnership, announced at a joint anniversary event in Tianjin, underscores both companies’ commitment to delivering integrated, end-to-end solutions for the global packaging and printing industry.

A Decade of Partnership Strengthening Global Reach

HEIDELBERG’s SHIFT 2025 Showcases AI-Driven Printing Workflows and Hybrid Production Future

Submitted by J. Mikhail on
Image
HEIDELBERG’s SHIFT 2025 Showcases AI-Driven Printing Workflows and Hybrid Production Future

SHERIDAN, WYOMING – October 15, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) brought together more than 200 global industry leaders at its new SHIFT 2025 summit to address one of the printing sector’s most pressing challenges: how to remain competitive amid rising costs, labor shortages, and increasingly fragmented order structures.

HEIDELBERG and Solenis Unveil Inline Barrier Coating Breakthrough for Sustainable Flexible Paper Packaging

Submitted by J. Mikhail on
Image
HEIDELBERG and Solenis Unveil Inline Barrier Coating Breakthrough for Sustainable Flexible Paper Packaging

SHERIDAN, WYOMING – October 15, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) and Solenis are redefining the future of sustainable packaging with a newly developed inline process that applies functional barrier coatings directly within the flexographic printing workflow. The innovation, integrated into HEIDELBERG’s high-volume Boardmaster system, aims to make paper-based flexible packaging a viable and economical alternative to plastic — accelerating the “paperization” trend across the global packaging industry.

EGGER Introduces DecoWall: A Sustainable, Design-Driven Solution for Modern Interior Professionals

Submitted by J. Mikhail on
Image
EGGER Introduces DecoWall: A Sustainable, Design-Driven Solution for Modern Interior Professionals

SHERIDAN, WYOMING – October 15, 2025 – EGGER, a leading European manufacturer of wood-based materials, has launched DecoWall, an innovative wall panel system that combines sustainable engineering with design flexibility for residential and commercial interiors. Designed to meet the growing demand for eco-conscious and easy-to-install wall solutions, DecoWall merges technical performance with aesthetic appeal — making it ideal for professional installers, architects, and designers seeking both function and form.